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Introduction 
 Impaired renal function alters the dose-effect relationship not only for drugs that are 
excreted by the kidney, but also for some drugs that are metabolized primarily by the liver and 
not renally excreted (Dreisbach and Lertora, 2008, Nolin et al., 2008). Warfarin is one such drug 
that is eliminated through hepatic metabolism and not directly excreted by the kidney (Ufer et al., 
2004). Recent studies reported that patients with impaired renal function had lower maintenance 
doses of warfarin than those with normal renal function in cohorts which consisted primarily of 
African and European Americans (Limdi, N. A. et al., 2009, Limdi, Nita A. et al., 2010). In Asian 
patients, however, the effect that decreased kidney function has on the maintenance dose of 
warfarin remains unclear. It is also unknown whether the maintenance dose of warfarin can be 
predicted more accurately by including renal function along with conventional demographic and 
genetic variables in Asians.  
In this cross-sectional study in Japanese patients, we examined: [1] whether the 
maintenance dose of warfarin has a correlation with renal function that is independent from other 
demographic, clinical, and genetic variables; and [2] whether the maintenance dose of warfarin 
can be predicted more accurately by including renal function along with other variables.  
Materials and Methods 
Japanese patients who were receiving a constant dose of warfarin for 3 months or longer 
and had a prothrombin time/international normalized ratio (PT-INR) of 1.5 to 3.0 on at least three 
consecutive visits during the same period were included. Patients who had either liver dysfunction, 
serum aminotransferase levels at least twice the upper limit of normal, or who were receiving 
chronic renal replacement therapy (e.g., hemodialysis) were excluded.  
Estimated creatinine clearance (eCrCl) was used as an estimate of kidney function of 
the patients based on clinical information. In addition, we categorized the patients into three 
groups based on their estimated glomerular filtration rate (eGFR). Estimated GFR ≥60 
ml/min/1.73 m2 were categorized as categories G1/G2; eGFR of ≥30 to <60 ml/min/1.73 m2 as 
categories G3a/G3b; and eGFR <30 ml/min/1.73 m2 as categories G4/G5. 
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Results 
There were 137 patients who fulfilled the conditions of the protocol and gave informed 
consent to participate in the study. The average dose of warfarin was 3.21 ± 1.46 mg/day. The 
average of eCrCl was 62.5 ± 25.5 ml/min.  
Warfarin dose was positively correlated with eCrCl (p < 0.0001, r2 = 0.23).  
There was a significant difference between the warfarin doses in patients with different 
categories of eGFR (p < 0.01). In a post-hoc comparison, warfarin doses in patients in eGFR 
categories G3a/G3b and G4/G5 were found to be significantly lower than that in patients in eGFR 
categories G1/G2 (2.88 ± 1.42 and 2.33 ± 1.04 mg/day vs. 3.54 ± 1.44 mg/day, p < 0.05). Patients 
in eGFR categories G4/G5 (n = 9) had a slightly, but not significantly lower warfarin dose than 
those in eGFR categories G3a/G3b (p = 0.28). 
 Based on a stepwise linear regression, age, body weight, genotype of VKORC1 -1639 
G>A polymorphism, eCrCl, and intra-individual average PT-INR were chosen as independent 
variables for a formula to predict warfarin maintenance dose. The derived formula with estimated 
parameters was as follows: 
Predicted warfarin maintenance dose (mg/day) =  
(-0.652) 
+ (-0.026) × age (years)  
+ (0.044) × body weight (kg)  
+ (1.861)    (if VKORC1 -1639 G>A genotype is not AA) 
+ (0.016) × eCrCl (ml/min) 
+ (0.747) × target PT-INR 
The coefficient of determination (r2) of this formula was 0.47. A regression equation with all the 
same explanatory variables except for eCrCl had an r2 of 0.41.  
Discussion 
We demonstrated for the first time to our knowledge, that eCrCl was positively 
correlated with warfarin maintenance dose in Asian patients. Warfarin doses in patients in eGFR 
categories G3a/G3b and G4/G5 were found to be significantly lower than that in patients in eGFR 
categories G1/G2. In a multivariate regression, adding eCrCl to age, body weight, VKORC1 -
1639 G>A genotype, and intra-individual average PT-INR as an independent variable increased 
accuracy in predicting warfarin dose.  
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